Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
前收盤價
US$28.00
+US$0.50 · +1.82%
盤前
US$27.94
−US$0.06 · -0.21%
10月8日 上午5:51 ET
盤中時間採用ET。市場資料可能有所延遲。
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
日內區間
目前US$28.00
52週區間
目前US$28.00
盤中時間採用ET。市場資料可能有所延遲。
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
日內區間
目前US$28.00
52週區間
目前US$28.00
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 625.79億 USD | 636.27億 USD | 595.53億 USD | 1003.3億 USD | 812.88億 USD |
| 銷貨成本 | 185.65億 USD | 217.81億 USD | 292.13億 USD | 382.4億 USD | 344.13億 USD |
| 毛利 | 440.14億 USD | 418.46億 USD | 303.4億 USD | 620.9億 USD | 468.75億 USD |
| 研究與開發 | 119.76億 USD | 107.38億 USD | 105.78億 USD | 114.26億 USD | 138.28億 USD |
| 銷售、一般及管理費用 | 133.46億 USD | 147.3億 USD | 144.7億 USD | 131.15億 USD | 122.54億 USD |
| 營業費用 | 285.77億 USD | 253.63億 USD | 250.48億 USD | 245.41億 USD | 260.82億 USD |
| 利息收入 | 6.03億 USD | 5.45億 USD | 16.24億 USD | 2.51億 USD | 3600萬 USD |
| 利息支出 | 26.71億 USD | 30.91億 USD | 22.09億 USD | 12.38億 USD | 12.91億 USD |
| 折舊和攤銷 | 65.92億 USD | 70.13億 USD | 62.9億 USD | 50.64億 USD | 51.91億 USD |
| 營業利益 | 154.37億 USD | 164.83億 USD | 52.92億 USD | 375.49億 USD | 207.93億 USD |
| 淨利 | 77.7億 USD | 80.2億 USD | 21.33億 USD | 313.65億 USD | 221.47億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$29.40
上漲空間 5.00%年度分割調整後的每股現金分配。
US$1.72
2025年(完整年度)+10.3% 自從 2021
2026年(部分年度):US$1.29
US$1.56
2,021
US$1.60
2,022
US$1.64
2,023
US$1.68
2,024
US$1.72
2,025
US$1.29
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息即將實施 | 2026年11月6日 | US$0.43Quarterly | 2026年11月6日 | 2026年12月7日 |
股息 | 2026年7月24日 | US$0.43Quarterly | 2026年7月24日 | 2026年9月1日 |
股息 | 2026年5月8日 | US$0.43Quarterly | 2026年5月8日 | 2026年6月12日 |
股息 | 2026年1月23日 | US$0.43Quarterly | 2026年1月23日 | 2026年3月6日 |
股息 | 2025年11月7日 | US$0.43Quarterly | 2025年11月7日 | 2025年12月1日 |
股息 | 2025年7月25日 | US$0.43Quarterly | 2025年7月25日 | 2025年9月2日 |
除息 2026年11月6日
US$0.43
Quarterly
2026年11月6日登記 · 支付日 2026年12月7日
除息 2026年7月24日
US$0.43
Quarterly
2026年7月24日登記 · 支付日 2026年9月1日
除息 2026年5月8日
US$0.43
Quarterly
2026年5月8日登記 · 支付日 2026年6月12日
除息 2026年1月23日
US$0.43
Quarterly
2026年1月23日登記 · 支付日 2026年3月6日
除息 2025年11月7日
US$0.43
Quarterly
2025年11月7日登記 · 支付日 2025年12月1日
除息 2025年7月25日
US$0.43
Quarterly
2025年7月25日登記 · 支付日 2025年9月2日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T3016.61億0.23%129.41兆 JPY0.09%¥122,700-0.57%
Vanguard Morningstar Total Stock Market ETFVTI51.55億0.22%2.3兆 USD0.03%US$381.03-0.40%
Vanguard S&P 500 ETFVOO43.1億0.24%1.8兆 USD0.03%US$714.34-0.26%
iShares Core S&P 500 ETFIVV20.88億0.23%8996.25億 USD0.03%US$780.58-0.25%
State Street SPDR S&P 500 ETFSPY19.05億0.23%8190.39億 USD0.09%US$777.22-0.24%
Vanguard Morningstar Value ETFVTV15.5億0.59%2624億 USD0.03%US$218.21-0.37%
State Street Health Care Select Sector SPDR ETFXLV11.14億2.58%431.09億 USD0.08%US$168.81+1.03%
Vanguard High Dividend Yield ETFVYM6.57億0.65%1008億 USD0.04%US$157.45-0.58%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLV
Vanguard High Dividend Yield ETFVYMAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。